•Forian's Chief Strategy Officer Adam Dublin reported the disposition of all common stock shares in connection with the company's merger and going-private transaction.
•Shares were transferred back to the issuer at $0.00 per share as Forian became a wholly-owned subsidiary of 2025 Acquisition Company, LLC.
•Unvested restricted stock units were cancelled and converted into a cash right based on $2.17 per share.
•Glucotrack received a Nasdaq delisting notice for failing to maintain a $1.00 minimum bid price and the $2.5 million stockholders' equity requirement.
•The company intends to request a hearing by May 18, 2026, which would temporarily stay the delisting process.
•Vivos Therapeutics announced a delay in filing its Form 10-Q for the quarter ended March 31, 2026, to consolidate financial data from its acquisition of The Sleep Center of Nevada.
•The company expects a larger net loss due to higher SG&A expenses related to SCN integration, despite preliminary figures showing revenue growth.
•YouTube and Snap reached settlements in the first case set for trial in litigation seeking to force social media platforms to cover costs related to youth mental health crises.